Literature DB >> 17277691

Spectrum of genotype and clinical manifestations in cerebral cavernous malformations.

Judith Gault1, Stephan Sain, Ling-Jia Hu, Issam A Awad.   

Abstract

OBJECTIVE: Cerebral cavernous malformations (CCMs) are focal dysmorphic blood vessel anomalies predisposing individuals to hemorrhagic stroke and epilepsy. CCMs are sporadic or inherited as autosomal dominant disease with three known genes. The hypothesis that genetic heterogeneity would account for the remarkable variability in CCM manifestations was tested.
METHODS: CCM cases were prospectively enrolled. Germline CCM1 gene mutations were sought in 89 CCM samples. Associations with clinical manifestations and lesion characteristics were made among 41 symptomatic familial cases, including one cohort of 26 cases with CCM1 mutations and a second cohort of 15 cases without identifiable CCM1 mutations. The 15 cases were screened for CCM2 and CCM3 mutations.
RESULTS: CCM1 mutations were found in 34 out of 50 subjects with familial disease and in none of 39 sporadic CCM cases. CCM2 and CCM3 mutations were found in three out of 10 families screened without CCM1 mutations. Clinical manifestations in 22 Hispanic-American cases with identical CCM1 mutations were highly variable. Fewer CCM1 patients experienced hemorrhage than others with familial disease (P = 0.0139 for all cases and P = 0.0442 for symptomatic cases). Adjusting for sex and age improved the logistic regression model, suggesting decreased numbers of patients with hemorrhage in CCM1 familial disease (P = 0.003 for all cases and P = 0.014 for symptomatic cases). Hemorrhage differences were not related to size or number of lesions.
CONCLUSION: Factors in addition to CCM1 germline mutation contribute to CCM clinical manifestations. However, this evidence suggests that familial cases with CCM1 mutations may have less severe clinical manifestations than other familial cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17277691     DOI: 10.1227/01.NEU.0000249188.38409.03

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  25 in total

Review 1.  Cavernous angiomas: deconstructing a neurosurgical disease.

Authors:  Issam A Awad; Sean P Polster
Journal:  J Neurosurg       Date:  2019-07-01       Impact factor: 5.115

Review 2.  From germline towards somatic mutations in the pathophysiology of vascular anomalies.

Authors:  Nisha Limaye; Laurence M Boon; Miikka Vikkula
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

Review 3.  Genetics of cerebral cavernous malformations: current status and future prospects.

Authors:  H Choquet; L Pawlikowska; M T Lawton; H Kim
Journal:  J Neurosurg Sci       Date:  2015-04-22       Impact factor: 2.279

4.  CCM3 Mutations Are Associated with Early-Onset Cerebral Hemorrhage and Multiple Meningiomas.

Authors:  F Riant; F Bergametti; H-D Fournier; F Chapon; S Michalak-Provost; M Cecillon; P Lejeune; H Hosseini; C Choe; M Orth; C Bernreuther; G Boulday; C Denier; P Labauge; E Tournier-Lasserve
Journal:  Mol Syndromol       Date:  2013-04-03

5.  Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations.

Authors:  Romuald Girard; Maged D Fam; Hussein A Zeineddine; Huan Tan; Abdul Ghani Mikati; Changbin Shi; Michael Jesselson; Robert Shenkar; Meijing Wu; Ying Cao; Nicholas Hobson; Henrik B W Larsson; Gregory A Christoforidis; Issam A Awad
Journal:  J Neurosurg       Date:  2016-08-05       Impact factor: 5.115

6.  A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease.

Authors:  Lisa McKerracher; Robert Shenkar; Matthew Abbinanti; Ying Cao; Amy Peiper; James K Liao; Rhonda Lightle; Thomas Moore; Nicholas Hobson; Carol Gallione; Joerg Ruschel; Janne Koskimäki; Romuald Girard; Kenneth Rosen; Douglas A Marchuk; Issam A Awad
Journal:  Transl Stroke Res       Date:  2019-08-24       Impact factor: 6.829

7.  Two-hit mechanism in cerebral cavernous malformation? A case of monozygotic twins with a CCM1/KRIT1 germline mutation.

Authors:  Philipp Dammann; Ute Hehr; Sabine Weidensee; Yuan Zhu; Rüdiger Gerlach; Ulrich Sure
Journal:  Neurosurg Rev       Date:  2013-04-13       Impact factor: 3.042

8.  Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.

Authors:  Rebecca A Stockton; Robert Shenkar; Issam A Awad; Mark H Ginsberg
Journal:  J Exp Med       Date:  2010-03-22       Impact factor: 14.307

9.  Immune response in human cerebral cavernous malformations.

Authors:  Changbin Shi; Robert Shenkar; Hongyan Du; Edward Duckworth; Harish Raja; H Hunt Batjer; Issam A Awad
Journal:  Stroke       Date:  2009-03-12       Impact factor: 7.914

10.  CCM molecular screening in a diagnosis context: novel unclassified variants leading to abnormal splicing and importance of large deletions.

Authors:  Florence Riant; Michaelle Cecillon; Pascale Saugier-Veber; Elisabeth Tournier-Lasserve
Journal:  Neurogenetics       Date:  2013-04-18       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.